CVRx (CVRX) Net Income towards Common Stockholders (2020 - 2026)

CVRx's (CVRX) quarterly Net Income towards Common Stockholders came in at -$13.1 million in Q1 2026, up 4.69% year-on-year from -$12.5 million in Q1 2025, and down 9.94% quarter-over-quarter from -$11.9 million in Q4 2025.

CVRx (CVRX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

CVRx's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$13.1 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 4.69% year-over-year to -$13.1 million in Q1 2026; TTM through Mar 2026 was -$52.7 million, a 2.14% decrease from a year earlier, with the FY2025 full-year figure at -$53.3 million, up 11.12% from the prior year.
  • Net Income towards Common Stockholders eased to -$13.1 million in Q1 2026 per CVRX's latest filing, from -$11.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$9.0 million in Q3 2023 and bottomed at -$22.2 million in Q1 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$11.7 million (2023), against an average of -$12.3 million.
  • Across the five-year window, Net Income towards Common Stockholders plunged 95.06% in 2024 and surged 37.95% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$10.5 million in 2022, then rose by 14.43% to -$9.0 million in 2023, then declined by 18.27% to -$10.7 million in 2024, then fell by 11.92% to -$11.9 million in 2025, then declined by 9.94% to -$13.1 million in 2026.
  • Per Business Quant, the three latest CVRX Net Income towards Common Stockholders figures stand at -$13.1 million (Q1 2026), -$11.9 million (Q4 2025), and -$12.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 1.08 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 745.00 Mn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 1.26 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 1.34 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 199.50 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn 411.00 Mn
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 176.78 Mn
10 CVRx 128.88 Mn 56.58 Mn 12.88 Mn -13.12 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -13.12 Mn
Dec 31, 2025 -11.93 Mn
Sep 30, 2025 -12.87 Mn
Jun 30, 2025 -14.74 Mn
Mar 31, 2025 -13.77 Mn
Dec 31, 2024 -10.66 Mn
Sep 30, 2024 -13.10 Mn
Jun 30, 2024 -14.03 Mn
Mar 31, 2024 -22.19 Mn
Dec 31, 2023 -9.02 Mn
Sep 30, 2023 -9.01 Mn
Jun 30, 2023 -11.65 Mn
Mar 31, 2023 -11.37 Mn
Dec 31, 2022 -10.54 Mn
Sep 30, 2022 -9.83 Mn
Jun 30, 2022 -11.07 Mn
Mar 31, 2022 -9.99 Mn
Dec 31, 2021 -10.57 Mn
Sep 30, 2021 -6.13 Mn
Jun 30, 2021 -17.75 Mn